Revel Pharmaceuticals Wants to Repair the Body’s Aging Scaffold

Field notes

The platform is organized around distinct molecular forms of structural-tissue damage rather than a single broad anti-aging claim. The page describes screening enzyme variants against real substrates, followed by hit identification and engineering, and names crystal accumulation, crosslink damage, and glycation as targets. It also links to a 2026 Nature Communications publication on enzymatic deglycation. The extract does not indicate whether the work has reached clinical testing or produced an approved therapy.